DDInter596 DDInter281
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Canakinumab
Doxorubicin {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Canakinumab
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Doxorubicin {u} (Compound) downregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Canakinumab
Doxorubicin {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Tuberculin purified protein derivative {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Doxorubicin {u} (Compound) downregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Norethisterone
Norethisterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Doxorubicin {u} (Compound) upregulates {v} (Gene) GNAI1
GNAI1 {u} (Gene) is upregulated by {v} (Compound) Alprazolam
Alprazolam {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Doxorubicin {u} (Compound) downregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is downregulated by {v} (Compound) Dactinomycin
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canakinumab
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Doxorubicin (Compound) binds NQO1 (Gene) and NQO1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Doxorubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Doxorubicin (Compound) binds NQO1 (Gene) and NQO1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Doxorubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Doxorubicin (Compound) upregulates GNAI1 (Gene) and GNAI1 (Gene) is upregulated by Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Doxorubicin (Compound) downregulates HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Dactinomycin (Compound) and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab